AIxCrypto Holdings (AIXC) Q3 2024 earnings summary

Executive summary

• Focused on early-clinical-stage cancer therapeutics, with QN-302 in Phase 1a trials and Pan-RAS in preclinical development.

• No revenue from product sales; business model relies on future commercialization and milestone/royalty payments.

• Entered a co-development agreement with Marizyme for DuraGraft, providing funding in exchange for future royalties.

Financial highlights

• Net loss from continuing operations was $1.8M for Q3 2024, down from $3.2M in Q3 2023; net loss for the nine months ended September 30, 2024 was $5.4M, down from $11.3M in the prior year period.

• General and administrative expenses decreased 15% year-over-year for Q3 and 38% for the nine months, mainly due to lower payroll, professional fees, and stock-based compensation.

• Research and development expenses dropped 91% year-over-year for Q3 and 68% for the nine months, reflecting reduced program costs and payroll.

• Cash and cash equivalents were $388K as of September 30, 2024, with an accumulated deficit of $122.2M.

Outlook and guidance

• Cash is expected to fund operations only into Q4 2024; substantial doubt exists about the ability to continue as a going concern without additional financing.

• Ongoing net losses and negative cash flow from operations are anticipated.

• No assurance of achieving profitable operations; further financing is uncertain.